BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8599870)

  • 1. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.
    Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR
    Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF; Hunakova L; Kelland LR
    Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
    O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
    Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA.
    Ormerod MG; O'Neill CF; Robertson D; Harrap KR
    Exp Cell Res; 1994 Apr; 211(2):231-7. PubMed ID: 8143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
    Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
    Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
    Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
    Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-proliferative activity and mechanism of action of titanocene dichloride.
    Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
    Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
    Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
    Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and repair of DNA double-strand breaks using constant-field gel electrophoresis and apoptosis as predictive markers for sensitivity of cancer cells to cisplatin.
    Saleh EM; El-Awady RA; Anis N; El-Sharkawy N
    Biomed Pharmacother; 2012 Oct; 66(7):554-62. PubMed ID: 22939736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
    Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
    Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
    Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
    Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.